Bausch + Lomb Co. to Post Q2 2024 Earnings of $0.20 Per Share, HC Wainwright Forecasts (NYSE:BLCO)

Bausch + Lomb Co. (NYSE:BLCO) – Stock analysts at HC Wainwright boosted their Q2 2024 earnings per share estimates for shares of Bausch + Lomb in a report issued on Thursday, May 2nd. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of $0.20 per share for the quarter, up from their previous estimate of $0.17. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Bausch + Lomb’s current full-year earnings is $0.65 per share. HC Wainwright also issued estimates for Bausch + Lomb’s Q3 2024 earnings at $0.26 EPS, FY2024 earnings at $0.89 EPS, Q1 2025 earnings at $0.24 EPS, Q2 2025 earnings at $0.26 EPS, Q3 2025 earnings at $0.25 EPS and Q4 2025 earnings at $0.29 EPS.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings data on Wednesday, May 1st. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.02). The firm had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.06 billion. Bausch + Lomb had a negative net margin of 7.81% and a positive return on equity of 3.57%. Bausch + Lomb’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.10 EPS.

BLCO has been the subject of a number of other reports. Royal Bank of Canada reduced their target price on shares of Bausch + Lomb from $20.00 to $18.00 and set an “outperform” rating for the company in a report on Monday, April 22nd. Wells Fargo & Company increased their price objective on Bausch + Lomb from $21.00 to $23.00 and gave the stock an “overweight” rating in a research report on Thursday, February 22nd. Evercore dropped their target price on Bausch + Lomb from $17.00 to $15.00 and set an “in-line” rating on the stock in a report on Thursday. Barclays increased their price target on Bausch + Lomb from $17.00 to $18.00 and gave the stock an “equal weight” rating in a report on Monday, February 26th. Finally, Evercore ISI boosted their price objective on shares of Bausch + Lomb from $16.50 to $17.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. Six research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Bausch + Lomb presently has a consensus rating of “Hold” and an average price target of $19.27.

Bausch + Lomb Stock Down 1.9 %

Shares of NYSE:BLCO opened at $13.60 on Friday. Bausch + Lomb has a 1-year low of $13.16 and a 1-year high of $21.95. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.74 and a quick ratio of 1.09. The stock has a market cap of $4.78 billion, a P/E ratio of -14.17, a P/E/G ratio of 1.33 and a beta of 0.47. The firm has a fifty day moving average price of $15.84 and a 200 day moving average price of $15.63.

Institutional Trading of Bausch + Lomb

A number of institutional investors have recently added to or reduced their stakes in the stock. Black Swift Group LLC acquired a new stake in Bausch + Lomb in the third quarter valued at $170,000. Jump Financial LLC acquired a new stake in Bausch + Lomb in the 3rd quarter valued at about $255,000. Renaissance Capital LLC increased its holdings in Bausch + Lomb by 27.3% during the 4th quarter. Renaissance Capital LLC now owns 22,407 shares of the company’s stock valued at $382,000 after acquiring an additional 4,801 shares in the last quarter. Quadrature Capital Ltd acquired a new position in Bausch + Lomb during the third quarter worth about $466,000. Finally, Allianz Asset Management GmbH acquired a new position in Bausch + Lomb during the fourth quarter worth about $1,706,000. Hedge funds and other institutional investors own 11.07% of the company’s stock.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.